US equities
|
MU
$953.19
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
MU
$953.19
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Kyverna Therapeutics, Inc. - Common Stock
(NQ:
KYTX
)
5.770
-0.440 (-7.09%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kyverna Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
October 07, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
September 24, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at Upcoming Investor Conferences
September 02, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
August 11, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
July 27, 2026
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
June 22, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
↗
June 08, 2026
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.
Via
The Motley Fool
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
June 03, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
May 18, 2026
Veteran biopharma leader joins to help lead Kyverna’s next phase of commercial growth
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at Upcoming Investor Conferences
May 14, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
May 12, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
May 04, 2026
Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations for a range of therapeutic areas
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Which stocks are moving before the opening bell on Wednesday?
↗
April 22, 2026
Via
Chartmill
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
↗
April 22, 2026
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.
Via
Benzinga
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
April 21, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
April 20, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
April 09, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 26, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
March 05, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
March 03, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
February 24, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 03, 2026
Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of...
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
January 12, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
January 05, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
On Thursday, there are stocks with unusual volume. Let's take a look.
↗
December 18, 2025
Let's have a look at the stocks with an unusual volume in today's session.
Via
Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
December 17, 2025
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
December 17, 2025
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
These stocks are gapping in today's session
↗
December 17, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.
Via
Chartmill
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
December 17, 2025
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
What's going on in today's pre-market session
↗
December 17, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
